Video

Dr. Konecny on Response to PARP Inhibitors in Ovarian Cancer

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

There are subsets of patients who derive great benefit from PARP inhibitors, and that should direct physicians’ treatment decisions, says Konecny. Additionally, physicians have to consider the potential toxicities of treatment or the potential cost of treatment as there are also patients who derive clinically less meaningful improvements.

PARP inhibition can be thought of as a targeted therapy in cells that have DNA repair-deficient mechanisms, says Konecny. Physicians need to have a reliable test or assay to select patients who may respond to PARP inhibition if these drugs are moved outside the realm of extreme platinum sensitivity.

Genomic scarring is a very stable feature, explains Konecny. Once a tumor develops genomic scarring, it has an increased fraction of DNA that is affected by gains or losses. Genomic scarring is something that stays throughout the further progression of disease. Therefore, it may be a combination of test assays, including sequencing, expression studies, and examining copy number changes that will give physicians a more reliable assay to specify which patients will respond to PARP inhibitors.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine